Marc Engelhardt

Chief Medical Officer at Basilea Pharmaceutica AG

Marc Engelhardt

Marc Engelhardt

Chief Medical Officer at Basilea Pharmaceutica AG

Biography

Marc Engelhardt is Chief Medical Officer at Basilea Pharmaceutica AG. Dr. Engelhardt previously was Director-Global Program Medical at Novartis Pharma AG. Dr. Engelhardt received a doctorate from Johann Wolfgang Goethe-Universität Frankfurt am Main.

Overview
RelSci Relationships

129

Number of Boards

1

Birthday

1964

Age

57
Relationships
View Relationship Details
RelSci Relationships are individuals Marc Engelhardt likely has professional access to. A relationship does not necessarily indicate a personal connection.
David Veitch

Chief Executive Officer at Basilea Pharmaceutica AG

Relationship likelihood: Strong

Adesh Kaul

Chief Financial Officer at Basilea Pharmaceutica AG

Relationship likelihood: Strong

Ronald Scott

Former Chief Executive Officer at Basilea Pharmaceutica AG

Relationship likelihood: Strong

Damian Heller

General Counsel & Corporate Secretary at Basilea Pharmaceutica AG

Relationship likelihood: Strong

Gerrit Hauck

Chief Technology Officer at Basilea Pharmaceutica AG

Relationship likelihood: Strong

Laurenz Kellenberger

Chief Scientific Officer at Basilea Pharmaceutica AG

Relationship likelihood: Strong

Ursula Eberhardt

Head of Global Human Resources at Basilea Pharmaceutica AG

Relationship likelihood: Strong

Josef Künzle

Head of Global Quality Management at Basilea Pharmaceutica AG

Relationship likelihood: Strong

Donato Spota

Senior Vice President & Chief Financial Officer at Hansa Biopharma AB

Relationship likelihood: Strong

Günter Ditzinger

Chief Technology Officer at Union Therapeutics A/S

Relationship likelihood: Strong

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.
In The News
Thomson Reuters ONE
January 11, 2021
Basilea gibt vorlaufige Umsatzzahlen fur 2020 bekannt und berichtet uber Fortschritte im Portfolio
GlobeNewswire
January 11, 2021
Basilea reports preliminary 2020 revenue and portfolio progress
Thomson Reuters ONE
October 12, 2020
Basilea berichtet uber Prasentation gepoolter Wirksamkeitsdaten fur Derazantinib bei iCCA-Patienten mit Mutationen und Amplifikationen der FGFR2 Gene auf dem ESMO MAP Virtual Congress 2020
GlobeNewswire
October 12, 2020
Basilea reports pooled efficacy data for derazantinib in iCCA patients with FGFR2 gene mutations and amplifications presented at ESMO MAP Virtual Congress 2020
Thomson Reuters ONE
September 29, 2020
Basilea initiiert zielgerichtete, Biomarker-basierte Phase-2-Studie mit Lisavanbulin bei Patienten mit Hirntumoren
Trending People
Henry L. "Hank" Aaron
SPORTS; RIP to Hammerin' Hank: He had all of the tools - Los Angeles Times
Boris Johnson
Rotting fish, lost business and piles of red tape. The reality of Brexit hits Br... - CNN
Jennifer Rene Psaki
Schumer: Trump impeachment trial to begin week of Feb. 8 - Associated Press
Thomas H. Gardner
Why NeuBase Therapeutics Popped by 16.5% on Friday - Nasdaq
Lloyd J. Austin III
Senate Confirms Austin in Historic Vote, Installing First Black Defense Secretar... - The New York Times
Trending People
Henry L. "Hank" Aaron
SPORTS; RIP to Hammerin' Hank: He had all of the tools - Los Angeles Times
Boris Johnson
Rotting fish, lost business and piles of red tape. The reality of Brexit hits Br... - CNN
Jennifer Rene Psaki
Schumer: Trump impeachment trial to begin week of Feb. 8 - Associated Press
Thomas H. Gardner
Why NeuBase Therapeutics Popped by 16.5% on Friday - Nasdaq
Lloyd J. Austin III
Senate Confirms Austin in Historic Vote, Installing First Black Defense Secretar... - The New York Times
Paths to Marc Engelhardt
Potential Connections via
Relationship Science
You
Marc Engelhardt
Chief Medical Officer at Basilea Pharmaceutica AG
Education
Johann Wolfgang Goethe-Universität Frankfurt am Main

The Goethe University Frankfurt (full German name: Johann Wolfgang Goethe-Universität Frankfurt am Main) is a university which was founded in 1914 as a Citizens' University, which means that, while it was a State university of Prussia, it had been founded and financed by the wealthy and active liberal citizenry of Frankfurt am Main, a unique feature in German university history. It was named in 1932 after one of the most famous natives of Frankfurt, the poet and writer Johann Wolfgang von Goethe. Today, the university has 38,000 students, on 4 major campuses. Until now Goethe University Frankfurt has produced 14 Nobel Prize winners, including 8 graduates.Being research focused, the university is an affiliate of 11 academics, who have been awarded the Gottfried Wilhelm Leibniz Prize, the highest research prize in Germany.

Career History
Chief Medical Officer
2018 - Current
Basilea Pharmaceutica AG

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX:BSLN). Through its fully integrated research and development operations the company focuses on the development of innovative antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.

Director-Global Program Medical
Prior
Novartis Pharma AG

Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland.

Other Affiliations

Marc Engelhardt is affiliated with Basilea Pharmaceutica AG, Novartis Pharma AG

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Marc Engelhardt. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Marc Engelhardt's profile does not indicate a business or promotional relationship of any kind between RelSci and Marc Engelhardt.